Codituss DM and Colistimethate Sodium

• Generic Name: dextromethorphan / phenylephrine / pyrilamine
• Dosage Forms: n.a.
• Other Brand Names: Codal-DM Syrup, Codimal DM, Codituss DM, Poly Hist DM, Viravan-DM, V-Tan DM, Zotex-12, Deconsal DM Tannate, Aldex DM, Viratan-DM, Triplex DM, MyHist-DM, Tannate V DM, Reme Hist DM, Pryil DM, Pyril DM

Dextromethorphan is a cough suppressant. It affects the signals in the brain that trigger cough reflex.

Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

Pyrilamine is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Codituss DM is a combination medicine used to treat cough, runny or stuffy nose, sneezing, itching, and watery eyes caused by allergies, the common cold, or the flu.

Codituss DM will not treat a cough that is caused by smoking, asthma, or emphysema.

Codituss DM may also be used for purposes not listed in this medication guide.

• Generic Name: colistimethate
• Dosage Forms: n.a.
• Other Brand Names: Coly Mycin M

Treatment of acute or chronic infections caused by certain susceptible gram-negative bacteria (e.g., Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa).

Used only when the causative agent is susceptible and other more effective and less toxic anti-infectives are contraindicated or ineffective.

May be useful alone or in conjunction with other anti-infectives for treatment of infections caused by multiple-drug resistant gram-negative bacteria, such as respiratory tract infections in cystic fibrosis patients caused by multiple-drug resistant Ps. aeruginosa.

Not indicated for infections caused by Proteus or Neisseria.

Administered by oral inhalation via nebulization in adult and pediatric cystic fibrosis patients for early treatment of Ps. aeruginosa respiratory tract infections and for suppressive therapy in those colonized with Ps. aeruginosa.

Safety and efficacy not established and the drug is not labeled by FDA for administration via nebulization. Adverse respiratory effects (e.g., bronchoconstriction) have occurred with this route and there has been at least one fatality in a patient who self-administered a nebulizer treatment using a premixed solution of the drug. (See Respiratory Effects under Cautions.)